MAVIRET (AbbVie Pty Ltd)
Product name
MAVIRET
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
181 working days (255)
Active ingredients
glecaprevir / pibrentasvir
Registration type
NCE/NBE
Indication
MAVIRET is indicated for the treatment of adult patients with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection with or without compensated cirrhosis. This includes patients with HCV genotype 1 infection who were previously treated with either a regimen of an NS5A inhibitor or with an NS3/4A protease inhibitor but not both classes of inhibitors.